AIm:The dose dependent effects of alpha lipoic acid (α-LA) were investigated morphologically on rat vasospasm model. mAterIAl and methOds: 32 rats were divided into four groups: group I=control; group II=vasospasm; group III=vasospasm +low dose (20 mg/kg) intraperitoneal α-LA administered; and group IV=vasospasm +high dose (100 mg/kg) intraperitoneal α-LA administered. Histological and morphometric examinations were carried out for each groups under light microscope.
results:The mean vascular wall thickness displayed significant increase in group II and III compared with group I (p<.05). Statistical comparison of group II and IV, regarding vascular wall thickness showed a significant decrease in group IV, and regarding vascular lumen area showed a significant increase in group IV (p<.05).COnClusIOn: It is demonstrated α-LA reduces the effects of vasospasm in high dose treatment group by decreasing the wall thickness and increasing the lumen surface area. The present study suggests that adequate dose of α-LA is a potential therapeutic agent in experimental vasospasm model. BulGulAr: Ana vasküler duvar kalınlığı grup II ve III'te grup I ile karşılaştırıldığında önemli bir artış göstermiştir (p<0,05). Grup II ve IV'ün istatistiksel olarak karşılaştırılması vasküler duvar kalınlığı açısından grup IV'te önemli bir azalma ve vasküler lümen açısından yine grup IV'te önemli bir artış göstermiştir (p<0,05). sOnuÇ: α-LA'nın yüksek doz tedavi grubunda duvar kalınlığını azaltıp lümen yüzey alanını arttırarak vazospazm etkilerini azalttığı gösterilmiştir. Mevcut çalışma yeterli dozda α-LA'nın deneysel bir vazospazm modelinde potansiyel bir terapötik ajan olduğunu düşündürmektedir.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.